Last reviewed · How we verify
VAQTA
VAQTA, marketed by Sanofi, is a vaccine that stimulates the immune system to produce antibodies against specific pathogens. A key strength of VAQTA is its established market presence, supported by a key composition patent that expires in 2028. The primary risk is the potential for increased competition as the patent expiration approaches.
At a glance
| Generic name | VAQTA |
|---|---|
| Also known as | VAQTA™, Inactivated Hepatitis A Vaccine, V251 |
| Sponsor | Sanofi |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection-site pruritus and/or rash
- Rash
- Pruritus
- Urticaria
- Edema/swelling
- Generalized erythema
- Eye irritation/itching
- Dermatitis
Serious adverse events
- Bronchial constriction
- Asthma
- Wheezing
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Belimumab in Autoimmune Hepatitis (PHASE2)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
- INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit (NA)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAQTA CI brief — competitive landscape report
- VAQTA updates RSS · CI watch RSS
- Sanofi portfolio CI